Prescient Therapeutics Ltd
ASX:PTX
Balance Sheet
Balance Sheet Decomposition
Prescient Therapeutics Ltd
Current Assets | 22.5m |
Cash & Short-Term Investments | 21m |
Receivables | 203.2k |
Other Current Assets | 1.3m |
Non-Current Assets | 3.4m |
PP&E | 3.9k |
Intangibles | 3.4m |
Other Non-Current Assets | 10 |
Current Liabilities | 1m |
Accounts Payable | 855.8k |
Accrued Liabilities | 118.2k |
Other Current Liabilities | 56.8k |
Non-Current Liabilities | 51.2k |
Other Non-Current Liabilities | 51.2k |
Balance Sheet
Prescient Therapeutics Ltd
Jun-2014 | Jun-2015 | Jun-2016 | Jun-2017 | Jun-2018 | Jun-2019 | Jun-2020 | Jun-2021 | Jun-2022 | Jun-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
4
|
1
|
10
|
8
|
5
|
10
|
7
|
16
|
12
|
6
|
|
Cash |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
16
|
12
|
2
|
|
Cash Equivalents |
4
|
1
|
10
|
8
|
5
|
10
|
0
|
0
|
0
|
4
|
|
Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
|
Total Receivables |
0
|
0
|
0
|
0
|
0
|
2
|
1
|
1
|
2
|
3
|
|
Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
|
Other Current Assets |
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Total Current Assets |
4
|
2
|
10
|
9
|
7
|
12
|
9
|
18
|
14
|
25
|
|
PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Intangible Assets |
1
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
|
Total Assets |
5
N/A
|
5
-7%
|
14
+183%
|
12
-12%
|
10
-18%
|
15
+50%
|
12
-20%
|
21
+74%
|
18
-16%
|
28
+60%
|
|
Liabilities | |||||||||||
Accounts Payable |
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
2
|
|
Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Current Liabilities |
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Liabilities |
0
N/A
|
0
+76%
|
1
+86%
|
0
-46%
|
1
+24%
|
1
+24%
|
1
+29%
|
1
-39%
|
1
+59%
|
2
+137%
|
|
Equity | |||||||||||
Common Stock |
43
|
44
|
54
|
55
|
56
|
64
|
64
|
77
|
77
|
93
|
|
Retained Earnings |
37
|
40
|
41
|
44
|
46
|
50
|
53
|
57
|
61
|
67
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Equity |
5
N/A
|
4
-12%
|
13
+192%
|
12
-9%
|
9
-20%
|
14
+52%
|
11
-22%
|
20
+83%
|
17
-18%
|
26
+56%
|
|
Total Liabilities & Equity |
5
N/A
|
5
-7%
|
14
+183%
|
12
-12%
|
10
-18%
|
15
+50%
|
12
-20%
|
21
+74%
|
18
-16%
|
28
+60%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
48
|
60
|
198
|
215
|
216
|
394
|
394
|
641
|
654
|
805
|